Merck Sharp & Dohme Corporation v Clonmel Healthcare Ltd

Core Citations

CONSIDERS

• Re Boehringer Ingelheim Pharma GmbH & Company Kg & Patents Acts

[See more]

• Ranbaxy Laboratories Ltd v Warner Lambert Company
• Eli Lilly and Company Ltd v Human Genome Sciences Inc. (No 2)
• Gilead Sciences Inc.

REPORTED OPINION OF in

• [2019] 11 JIC 2905

CONSIDERED in

• Merck Sharp and Dohme Corporation v Clonmel Healthcare Ltd
• Merck Sharp & Dohme Ltd v Clonmel Healthcare Ltd
• Merck Sharp & Dohme LLC v Mylan Ire Healthcare Ltd and Mylan Ireland Ltd and McDermott Laboratories T/A as Gerard Laboratories T/A as Mylan Dublin

AFFIRMED in

• Merck Sharp and Dohme Corporation v Clonmel Healthcare Ltd

This document cites

• Withler v. Canada (Attorney General), [2011] N.R. TBEd. MR.002
• Yeda Research and Development Company Ltd v Comptroller General of Patents
• Ranbaxy Laboratories Ltd v Warner Lambert Company
• Re Boehringer Ingelheim Pharma GmbH & Company Kg & Patents Acts
• Eli Lilly and Company Ltd v Human Genome Sciences Inc. (No 2)



See all quotations

• Gilead Sciences Inc.
• Teva UK Ltd and Others v Gilead Sciences Inc.
• Pharmacia Italia SpA, formerly Pharmacia & Upjohn SpA.
• Medeva BV v Comptroller General of Patents, Designs and Trade Marks.
• Eli Lilly and Company Ltd v Human Genome Sciences Inc.
• Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use
• Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (Codified version) (Text with EEA relevance)
• Directive 2002/20/EC of the European Parliament and of the Council of 7 March 2002 on the authorisation of electronic communications networks and services (Authorisation Directive)